Catheter Precision (NYSEAMERICAN:VTAK) Announces Earnings Results, Beats Expectations By $18.08 EPS

Catheter Precision (NYSEAMERICAN:VTAK) announced its earnings results on Friday. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($19.00) by $18.08, FiscalAI reports. The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $2.00 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

Catheter Precision Trading Down 3.4%

Shares of Catheter Precision stock traded down $0.01 during trading hours on Friday, reaching $0.28. 678,362 shares of the company’s stock were exchanged, compared to its average volume of 4,579,099. Catheter Precision has a 52-week low of $0.23 and a 52-week high of $4.31. The company has a fifty day moving average of $0.68 and a 200-day moving average of $1.05. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $1.01 million, a price-to-earnings ratio of -0.02 and a beta of -1.00.

Hedge Funds Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent quarter. Institutional investors own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.